
Selective av integrin depletion identifies a core, targetable molecular pathway that regulates fibrosis across solid organs


Neil C Henderson*, Thomas D Arnold, Yoshio Katamura, Marilyn M Giacomini, Juan D Rodriguez, Joseph H McCarty, Antonella Pellicoro, Elisabeth Raschperger, Christer Betsholtz, Peter G Ruminski, David W Griggs, Michael J Prinsen, Jacquelyn J Maher, John P Iredale, Adam Lacy-Hulbert, Ralf H Adams, Dean Sheppard*

*Address correspondence to: Neil Henderson (e-mail: Neil.Henderson@ed.ac.uk) or Dean Sheppard (e-mail: Dean.Sheppard@ucsf.edu).




Supplementary Figure 1: *Pdgfrb*-Cre effectively targets recombination in HSC, quiescent mouse HSC express PDGFRβ, and analysis of protein expression in TdTomato positive cells sorted from Ai14;*Pdgfrb*-Cre reporter mice.

(a) Recombination efficiency in livers from control or chronic CCl₄ treated Ai14;*Pdgfrb*-Cre reporter mice (n = 4 male mice per group) stained for desmin, PDGFR β or α SMA. (b) Immunofluoresence micrographs of liver sections from control (upper) or chronic CCl₄ treated (lower) Ai14;*Pdgfrb*-Cre reporter mice (n = 4 male mice per group) stained for endothelium (CD31, green), kupffer cells (F4/80, green), lymphocytes (CD3, green) and biliary epithelium (pan-cytokeratin, green) with endogenous Td tomato report in red. Scale bars, 25 µm (CD31, CD3 and pan-cytokeratin) and 50µm (F4/80). (c) Immunofluoresence micrographs of liver sections from uninjured *Pdgfrb*-BAC-eGFP reporter mice (n = 4 male mice) stained for desmin and PDGFR β (red), α SMA (blue) and endogenous *Pdgfrb*-BAC-eGFP reporter mice (n = 4 male mice) in uninjured livers from *Pdgfrb*-BAC-eGFP mice. (e) Western blotting of α SMA and desmin expression in freshly sorted Td tomato positive cells from control or chronic CCl₄ treated Ai14;*Pdgfrb*-Cre mice. (f,g) Total TGF- β 1 and TIMP1 concentrations in cell lysates from freshly sorted Td tomato positive cells from control or chronic CCl₄ treated Ai14;*Pdgfrb*-Cre mice. n = 4 male mice per group. Data are mean \pm s.e.m. **P < 0.01 (Student's *t* test).




Supplementary Figure 2: Hepatic myofibroblasts express av integrin in human fibrotic liver tissue, and av integrin depletion on murine HSCs does not affect initial liver injury after CCl₄ treatment, baseline HSC number, inflammatory infiltrates or the vasculature of *itgav*^{flox/flox};*Pdgfrb*-Cre livers.


(a) Representative immunofluorescence micrographs of human fibrotic liver tissue stained for αv integrin (red), α SMA (green) and DAPI (blue) (n = 5 cases). Arrow (right panel) indicates αv integrin and α SMA double-positive cell. Scale bar, 10 µm. (b) Micrographs of hematoxylin / eosin stained liver sections from control or *itgav^{flox/flox};Pdgfrb*-Cre (αv Cre) mice 24 h after a single i.p. injection of olive oil or CCl₄ (n = 6 male mice per group). Scale bar, 200µm. (c) Serum alanine aminotransferase (ALT) levels. (d,e) Digital image analysis of desmin and PDGFR β staining in uninjured control and *itgav^{flox/flox};Pdgfrb*-Cre livers (n = 6 male mice per group). (f) Gr1 immunohistochemistry of liver tissue after control or chronic CCl₄ treatment of control and *itgav^{flox/flox};Pdgfrb*-Cre mice. (n = 8 male mice per group). Scale bar, 50µm. (g) Neutrophil counting. (h) F4/80 immunohistochemistry of liver tissue after control or chronic CCl₄ treatment of control and *itgav^{flox/flox};Pdgfrb*-Cre mice. Scale bar, 200µm. (i) Digital image analysis quantification of F4/80 staining. (j) CD31 immunohistochemistry of liver tissue (left) after control or chronic CCl₄ treatment of control and *itgav^{flox/flox};Pdgfrb*-Cre mice. Scale bar, 100µm. Digital image analysis quantification of CD31 staining (right). Data are mean \pm s.e.m. (Student's *t* test).



Supplementary Figure 3: αv integrin and PDGFR β expression in purified hepatic cell populations from *itgav*^{flox/flox};*Pdgfrb*-Cre mice, total TGF- β 1 concentrations in control and *itgav*^{flox/flox};*Pdgfrb*-Cre HSCs, and addition of TGF- β 1 to *itgav*^{flox/flox};*Pdgfrb*-Cre HSCs rescues pro-fibrotic gene expression. (a) Western blotting of αv integrin and PDGFR β expression in purified hepatocytes (Hep), liver sinusoidal endothelial cells (LSECs), kupffer cells and HSCs from control and *itgav*^{flox/flox};*Pdgfrb*-Cre (αv Cre) male mice 5 days post isolation. (b) Total TGF- β 1 concentrations measured by ELISA in cell lysates from control and *itgav*^{flox/flox};*Pdgfrb*-Cre HSCs cultured with and without TMLCs (c) Total TGF- β 1 concentrations measured by ELISA in supernatants from control and *itgav*^{flox/flox};*Pdgfrb*-Cre (αv Cre) HSCs treated with control or recombinant TGF- β 1 (1ng ml⁻¹) for 24 h. (e) qPCR analysis of *Col1A1* expression in control and *itgav*^{flox/flox};*Pdgfrb*-Cre (αv Cre) HSCs treated with control and *itgav*^{flox/flox};*Pdgfrb*-Cre (αv Cre) HSCs treated with control or recombinant TGF- β 1 (1ng ml⁻¹) for 24 h. (e) qPCR analysis of *Col1A1* expression in control and *itgav*^{flox/flox};*Pdgfrb*-Cre (αv Cre) HSCs treated with control and *itgav*^{flox/flox};*Pdgfrb*-Cre (αv Cre) HSCs treated with control and *itgav*^{flox/flox};*Pdgfrb*-Cre (αv Cre) HSCs treated with control or recombinant TGF- β 1 (1ng ml⁻¹) for 24 h. (e) qPCR analysis of *Col1A1* expression in control and *itgav*^{flox/flox};*Pdgfrb*-Cre (αv Cre) HSCs treated with control or recombinant TGF- β 1 (1ng ml⁻¹) for 24 h. Data are mean \pm s.e.m. *P < 0.05, **P < 0.01 (Student's *t* test).




Supplementary Figure 4: TGF- β 1 expression in hepatic cell populations isolated from CCl₄-induced fibrotic liver, and assessment of adhesion, migration and anoikis in control and *itgav*^{flox/flox};*Pdgfrb*-Cre HSCs. (a) qPCR analysis of *TGFb1* mRNA expression in purified HSCs, hepatocytes, liver sinusoidal endothelial cells (LSECs) and kupffer cells isolated from CCl₄-induced fibrotic livers (n = 4 male mice per group). (b) Adhesion assay of control and *itgav*^{flox/flox};*Pdgfrb*-Cre HSCs plated on different matrices. (c) Migration assay of control and *itgav*^{flox/flox};*Pdgfrb*-Cre HSCs (d) TUNEL immunofluorescence staining of control and *itgav*^{flox/flox};*Pdgfrb*-Cre HSCs. Arrows indicate TUNEL positive nuclei (green), DAPI (blue). (e) Quantitation of TUNEL-positive nuclei. Data are mean \pm s.e.m. (Student's *t* test).




Supplementary Figure 5: FACS analysis of $\alpha 1$, $\alpha 5$ and $\beta 1$ integrin expression levels in control and *itgav*^{flox/flox};*Pdgfrb*-Cre HSCs, and recombination efficiency in lung pericytes and myofibroblasts in Ai14;*Pdgfrb*-Cre mice.

FACS analysis of (a) $\alpha 1$, (b) $\alpha 5$ and (c) $\beta 1$ integrin expression levels in control and *itgav*^{flox};*Pdgfrb*-Cre HSCs cultured on tissue culture plastic for 5 days. (d) Analysis of recombination efficiency in lungs from saline treated (control) or bleomycin treated Ai14;*Pdgfrb*-Cre reporter mice (n = 4 male mice per group) stained for desmin, PDGFR β or α SMA. Data are mean \pm s.e.m.




Supplementary Figure 6: Myofibroblast induction in Ai14-Td tomato positive cells sorted from lungs and kidneys of Ai14; Pdgfrb-Cre mice, and analysis of av and β6 integrin expression in uninjured and fibrotic lung, liver and kidney in control and *itgav^{flox/flox}:Pdgfrb*-Cre mice. (a) Western blotting of α SMA in freshly sorted Td tomato positive cells from saline or bleomycin treated (28 days post instillation) Ai14; Pdgfrb-Cre mice (n = 4 male mice per group). (b) Immunofluoresence staining of Td tomato positive cells sorted from the uninjured lungs of Ai14; Pdgfrb-Cre mice and plated on tissue culture plastic for 7 days. Endogenous report (red), αSMA (green), DAPI (blue). Scale bar, 100μm. (c) Western blotting of α SMA in freshly sorted Td tomato positive cells from sham operated or UUO (day 7) Ai14;*Pdgfrb*-Cre mice (n = 4 male mice per group). (d) Immunofluoresence staining of Td tomato positive cells sorted from the uninjured kidneys of Ai14; Pdgfrb-Cre mice and plated on tissue culture plastic for 7 days. (e) Western blotting of αv expression in whole lung homogenates from saline or bleomycin treated control and $itgav^{flox/flox}$: Pdgfrb-Cre (av Cre) mice. n = 5 male mice per group. (f) Representative sections of av $\beta 6$ immunohistochemistry in lungs from saline or bleomycin treated control and itgav^{flax/flax}; Pdgfrb-Cre (av Cre) mice. Scale bar, 50 µm. (g) Western blotting of av expression in whole liver homogenates from olive oil or CCl₄ treated control and $itgav^{flox/flox}$; Pdgfrb-Cre (αv Cre) mice. n = 5 male mice per group. (h) Representative sections of $\alpha\nu\beta6$ immunohistochemistry in livers from olive oil or CCl, treated control and *itgav^{flox/flox}:Pdgfrb*-Cre ($\alpha\nu$ Cre) mice. Arrows indicate $\alpha\nu\beta6$ positive biliary epithelium. Scale bar, 50 μ m. (i) Western blotting of $\alpha\nu$ expression in whole kidney homogenates from sham operated or UUO (day 14) control and *itgav^{flox/flox}; Pdgfrb*-Cre (αv Cre) mice. n = 5 male mice per group. (i) Representative sections of ανβ6 immunohistochemistry in kidneys from sham operated or UUO (day 14) control and *itgav^{flax/flax};Pdgfrb*-Cre (αv Cre) mice. Scale bar, 50 µm.



Supplementary Figure 7: Inhibition of av integrins by the novel small molecule CWHM 12.

(a) Chemical structure of CWHM 12. (b) Chemical structure of CWHM 96 (control R-enantiomer of CWHM 12). (c–g) Ligand-binding functions of $\alpha\nu\beta1$, $\alpha\nu\beta3$, $\alpha\nu\beta5$, $\alpha\nu\beta6$ and $\alpha\nu\beta8$ were measured as described in Materials and Methods. Representative CWHM 12 and CWHM 96 inhibition curves are shown for each assay. (h–j) Ligand-binding functions of α IIb $\beta3$, $\alpha2\beta1$ and $\alpha10\beta1$ were measured as described in Materials and Methods. Representative CWHM 12 and CWHM 96 inhibition curves are shown for each assay. (k) Mean IC50 values and standard deviation from at least two identical experiments are summarized.



Supplementary Figure 8: Phospho-SMAD3 signaling is reduced in the livers of CWHM 12 treated mice following chronic CCl₄ administration, and treatment with CWHM 96 (control R-enantiomer of CWHM 12) does not inhibit liver fibrosis.

(a) Immunofluoresence micrographs of liver sections from control and CWHM 12 treated mice following chronic CCl₄ treatment (n = 14 male mice per group). Scale bar, 25 µm. (b) Digital image analysis quantification of phospho-SMAD3 staining. (c) Dosing regime in the CWHM 96 (control R-enantiomer of CWHM 12) liver fibrosis model. Mice were given CCl₄ I.P. twice weekly for 3 weeks, then Alzet osmotic minipumps containing either CWHM 96 or vehicle (50% DMSO) were inserted, followed by a further 3 weeks of CCl₄ I.P. twice weekly. (d) Picrosirius red staining of liver tissue from vehicle control and CWHM 96 treated mice (n = 10 male mice per group) after chronic CCl₄ treatment. Scale bar, 200µm. (e) Digital image analysis quantification of collagen (picrosirius red) staining. (f) Hydroxyproline analysis. Data are mean \pm s.e.m. **P < 0.01 (Student's *t* test).